Gracell Biotechnologies Inc (GRCL US)

Analysis

Health Care • United States

Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.

Refresh

Company Presentation • 13 Dec 2023 20:00

Corporate Presentation

Company Presentation • 01 Nov 2023 20:00

Investor Presentation

Company Presentation • 14 Jun 2021 20:00

Status Update

Company Presentation • 17 Aug 2021 20:00

Q2 2021

Company Presentation • 14 Mar 2022 20:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Corporate Presentation

Investor Presentation

Status Update

Q2 2021

Q4 2021